Dr. Jason Hsu and his team (Ophthalmic Consultants of Boston, Boston, Massachusetts; Retinal Consultants of Houston, Houston, Texas; Retina Service of Wills Eye Hospital and Mid Atlantic Retina, Philadelphia, Pennsylvania; Associated Retinal Consultants, Royal Oak, Michigan) performed a multicenter randomized placebo-controlled clinical trial in which patients with nAMD who were suboptimal responders despite frequent anti-VEGF injections were randomized to use either dorzolamide-timolol drops or artificial tears.16 Eligible patients were 45 years or older with nAMD who were receiving ranibizumab or aflibercept injections at 4 - 6 week intervals (i.e., at least four injections within six months prior to enrollment) and had evidence of persistent exudation, which was defined as intraretinal or subretinal fluid on optical coherence tomography (OCT). They must have received the same anti-VEGF agent for two consecutive visits with an injection interval of 4 - 6 weeks. Finally, the patients needed a baseline central subfield thickness (CST) of at least 270 μm on OCT.
"Off Label Innovation: Discovering New Uses for Glaucoma Drops,"
inSIGHT: Vol. 1:
1, Article 4.
Available at: https://jdc.jefferson.edu/insight/vol1/iss1/4